Sanitation: Asthma drug may improve cancer therapy

Health Rounds

By Nancy Lapid, Health Science Editor

Welcome to Health Rounds! Immunotherapies are among the most important and biggest-selling medicines in the cancer-fighting arsenal, and today we feature an early study that found they may be improved by adding a readily available asthma drug. We also report on a potential new use for another approved medicine that helped reduce suicidal thoughts in patients with severe depression when added to the psychedelic drug ketamine.

Among our breaking news stories: US health department withdraws vaccine advisory panel charter; US Supreme Court rebuffs pharma challenge to Biden-era drug price; and US states reject anti-vaccine bills as public health groups fight MAHA.

Also: TrumpRx drug site to list 600 generics; Trump's psychedelic drug order boosts investor interest; and Colorado top court says hospital must resume treatments for transgender youth.

The latest on Hantavirus and Ebola: Adult dies of hantavirus in Colorado; Britain gets experimental Japanese antiviral for hantavirus response; Ebola deaths in eastern Congo rise to 131, while test shortages slow the fight; health workers race to respond to the fast-spreading outbreak; flawed tests and funerals allowed Ebola to spread undetected; and health experts meet in search of Ebola Bundibugyo vaccine options.

Industry Updates

US Supreme Court turns away Eli Lilly whistleblower law challenge.
AstraZeneca blood pressure drug wins U.S. approval.
Merck drug helps uterine cancer patients live longer.
Roche, Medicines Patent Pool to expand access to influenza drug.
Nestle and Danone face fresh scrutiny over infant formula recalls.
Boston Scientific invests $1.5 billion in MiRus.
Bayer agrees to pay $133 million for PCB cleanup in two states.
Sanofi rare lung disease drug outperforms standard care.
Takeda convicted of antitrust scheme to delay generic drug.
Commure valued at $7 billion, raises $70 million.
Relay's treatment shrinks vascular malformations.
Hansa strikes $134 million deal with SERB for kidney drug.
Apnimed sleep apnea pill meets main goal in late-stage study.
BioMarin's genetic disease therapy shows mixed results.
Regeneron drops after skin cancer treatment fails late-stage trial.
Advanced Medical Solutions shares fall after failed buyout talks.

What do we know about the Bundibugyo strain of the Ebola virus?

REUTERS/Jean Bizimana

A rare strain of Ebola is causing disease and deaths in the Democratic Republic of Congo and Uganda, prompting the World Health Organization to declare a public health emergency of international concern. Here is what we know about this strain, known as Bundibugyo.

Study Rounds

Asthma drug may boost cancer immunotherapy

The common asthma drug montelukast may boost the effectiveness of cancer immunotherapies, new research suggests.

Montelukast, sold under the brand name Singulair by Organon and available in generic versions, blocks a key molecule called CysLTR1 that plays a role in asthma. The molecule is also used by tumors to suppress the body's immune defenses, researchers found in lab experiments.

By blocking CysLTR1 and restoring those immune defenses, montelukast improves the effectiveness of cancer immunotherapy drugs, according to a report of the study published in Nature Cancer.

In test tube experiments with human cancer cells and in mice with various types of cancer, researchers found tumors “turn on” CysLTR1 to increase production of so-called polymorphonuclear myeloid-derived suppressor cells, which resemble immune cells called neutrophils but which actually suppress tumor-fighting immune defenses.

“When we turned off this switch, either genetically or with (montelukast), we not only slowed tumor growth, but also helped the immune system recover its ability to fight the cancer,” study leader Dr. Bin Zhang of Northwestern University Feinberg School of Medicine in Chicago said in a statement.

Because montelukast and other drugs that block CysLTR1 are already FDA-approved, patient trials could start soon, the researchers said.

“We may be able to quickly and safely test it in cancer patients to improve immunotherapy. Especially in aggressive cancers, like triple-negative breast cancer, where new options are urgently needed,” Zhang said.

“The next steps are to confirm this mechanism in patients, identify who will benefit most, optimize how we use these drugs especially in combination with immunotherapy, and begin carefully designed clinical trials.”

Short course of opioid abuse drug improves ketamine response

Adding a low dose of buprenorphine after a single treatment with the psychedelic drug ketamine may significantly reduce thoughts of suicide in patients with severe depression, researchers say.

U.S. President Donald Trump recently signed an executive order directing health regulators to speed research into uses of psychedelic treatments.

Ketamine is known to reduce suicidal thoughts very quickly, often within hours, but the effect generally does not last long, the researchers said.

In the study, 50 adults with major depression and clinically significant suicidal ideation received a single infusion of ketamine and two days later were randomly assigned to receive either low-dose buprenorphine or a placebo for four weeks. Buprenorphine is typically used to treat opioid use disorders or pain.

By week four, depression in both groups had improved to a similar extent, but suicidal ideation had decreased by 76% in the buprenorphine group, compared to 43% among those who received a placebo, according to a report published in the American Journal of Psychiatry to coincide with a presentation at the American Psychiatric Association meeting in San Francisco.

There are currently no FDA-approved medications specifically indicated to reduce suicidal ideation in major depressive disorder, the researchers noted.

"This is the second trial to indicate that buprenorphine at low doses reduces suicidal ideation in major depression,” study leader Dr. Allen Schatzberg of Stanford University School of Medicine said in a statement.

“However, unlike earlier reports, the degree of reduction was enhanced markedly by pre-treating with intravenous ketamine,” he added.

The authors noted that because the small study excluded individuals with substance use disorders, more research is needed to confirm the findings and determine optimal treatment durations.

In case you missed it...

This newsletter was edited by Bill Berkrot; additional reporting by Shawana Alleyne-Morris.

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website

Reuters Health Rounds is sent twice a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.

This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.

Terms & Conditions